Comparison of 18f fdg pet-ct and cect in pretreatment staging of adults with hodgkin ’s lymphoma

Hodgkin Lymphoma (HL) is a chemo-radiosensitive cancer with a five-year survival rate over 85% with current therapies [1]. However, there are serious long-term therapy related adverse events such as second cancers, cardiac and peripheral vascular disease, pulmonary disease, infertility, sexual dysfunction, etc. Therefore, it is extremely important to reduce the long-term side effects, reducing the amount and toxicity of poly-chemotherapies and improving staging procedures [2,3].

Source: Leukemia Research - December 5, 2018 Category: Hematology Authors: Martina Panebianco, Oreste Bagni, Natalia Cenfra, Sergio Mecarocci, Elettra Ortu La Barbera, Luca Filippi, Giovanni Codacci-Pisanelli, Tommaso Biondi, Andrea Laghi, Giuseppe Cimino Tags: Research paper Source Type: research